Compare AbbVie Inc (ABBV) vs SkyWest Inc (SKYW) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

SkyWest (SKYW) trades at $111.84, down 1.41% on the day, with a bullish technical signal supported by moving averages and a consensus analyst buy rating. Recent Q2 2026 earnings missed estimates at $2.54 EPS versus $2.70 expected, but revenue trends show growth to $4.2B in 2026. The stock benefits from strong profitability with a 9.78% net margin and attractive valuation metrics, including a P/E of 10.69. Key developments include executive stock sales and a 7.7% post-earnings rally noted by Zacks on July 27, 2026.

Outlook remains positive due to undervaluation and fleet expansion, but risks include fuel cost volatility from Iran war impacts (New York Post, July 7, 2026) and insider selling. The consensus price target of $109.33 suggests limited upside, with execution on earnings beats being critical for further gains.